Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS

• Published in: Expert opinion on biological therapy Vol. 13; no. 3; p. 437
• Main Authors: Chung, Janet, DiGiusto, David L, Rossi, John J
• Format: Journal Article
• Language: English
• Published: England 01.03.2013
• Subjects: Cell- and Tissue-Based Therapy; Combined Modality Therapy; Genetic Therapy; Hematopoietic Stem Cells; HIV Infections - genetics; HIV Infections - therapy; HIV-1 - physiology; Humans; RNA - genetics
• DOI: 10.1517/14712598.2013.761968

HIV/AIDS continues to be a worldwide health problem and viral eradication has been an elusive goal. HIV+ patients are currently treated with combination antiretroviral therapy (cART) which is not curative. For many patients, cART is inaccessible, intolerable or unaffordable. Therefore, a new class of therapeutics for HIV is required to overcome these limitations. Cell and gene therapy for HIV has been proposed as a way to provide a functional cure for HIV in the form of a virus/infection resistant immune system. In this review, the authors describe the standard therapy for HIV/AIDS, its limitations, current areas of investigation and the potential of hematopoietic stem cells modified with anti-HIV RNAs as a means to affect a functional cure for HIV. Cell and gene therapy for HIV/AIDS is a promising alternative to antiviral drug therapy and may provide a functional cure. In order to show clinical benefit, multiple mechanisms of inhibition of HIV entry and lifecycle are likely to be required. Among the most promising antiviral strategies is the use of transgenic RNA molecules that provide protection from HIV infection. When these molecules are delivered as gene-modified hematopoietic stem and progenitor cells, long-term repopulation of the patient's immune system with gene-modified progeny has been observed.